Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (857)	10/5/1998 12:52:00 PM
From: aknahow	Read Replies (1) \| Respond to of 1722

Nice article on Merck page 78 of Oct. 12 Business Week. Don't know if you have already posted this. Believe it is probably online and free.

To: Anthony Wong who wrote (857)	10/5/1998 9:03:00 PM
From: Anthony Wong	Respond to of 1722

Johnson & Johnson Rated New 'Market Perform' at J.P. Morgan Bloomberg News October 5, 1998, 9:39 a.m. ET Princeton, New Jersey, Oct. 5 (Bloomberg Data) -- Johnson & Johnson (JNJ US) was rated ''market perform'' in new coverage by analyst Michael N. Weinstein at J.P. Morgan Securities. -- Michael Donohue in Princeton, New Jersey, (609)279-3156

To: Anthony Wong who wrote (857)	10/5/1998 9:06:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 1722

J&J to Buy FemRx for $22 Mln for Gynecology Line Bloomberg News October 5, 1998, 5:09 p.m. ET J&J to Buy FemRx for $22 Mln for Gynecology Line New Brunswick, New Jersey, Oct. 5 (Bloomberg) -- Johnson & Johnson said it will buy FemRx Inc., a maker of medical products for diagnosing and treating gynecological disorders, for about $22 million in cash to bolster its women's health-products line. Johnson & Johnson, the world's fifth-largest drugmaker and one of the biggest makers of medical devices, said it will pay about $2.35 a share for FemRx, a 30 percent premium to FemRx's closing price of 1 13/16 on Friday. Shares of FemRx rose 3/8 to 2 3/16 today. Johnson & Johnson said it will soon start a tender offer for all of FemRx's 9.4 million common shares and equivalents. Sunnyvale, California-based FemRx makes surgical systems that provide alternatives to a hysterectomy, surgery to remove a woman's uterus. New Brunswick, New Jersey-based Johnson & Johnson will add FemRx to its Ethicon division, which makes medical supplies including products that help treat female infertility, uterine problems and incontinence. Shares of Johnson & Johnson rose 2 5/16 to 79 7/16. --Marion Gammill in the Princeton newsroom (609) 279-4097/rjb/gfh